Selck et al., 2021 - Google Patents

Regulatory T Cells for the Treatment of Autoimmune Diseases

Selck et al., 2021

Document ID
5687754353916684580
Author
Selck C
Dominguez-Villar M
Publication year
Publication venue
Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases

External Links

Snippet

Regulatory T (Treg) cells play a critical role in inflammatory responses and maintenance of self-tolerance. Various Treg cell deficiencies have been detected in animal models of autoimmunity and patients with autoimmune disorders. While the exact molecular …
Continue reading at www.taylorfrancis.com (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses

Similar Documents

Publication Publication Date Title
Scheinecker et al. Treg cells in health and autoimmune diseases: New insights from single cell analysis
Georgiev et al. Regulatory T cells: the many faces of Foxp3
Kitz et al. Regulatory T cells: from discovery to autoimmunity
Schmidt et al. Comparative analysis of protocols to induce human CD4+ Foxp3+ regulatory T cells by combinations of IL-2, TGF-beta, retinoic acid, rapamycin and butyrate
Kleinewietfeld et al. Regulatory T cells in autoimmune neuroinflammation
Togashi et al. Regulatory T cells: molecular and cellular basis for immunoregulation
Sakaguchi et al. FOXP3+ regulatory T cells in the human immune system
Marek‐Trzonkowska et al. Clinical application of regulatory T cells in type 1 diabetes
Podojil et al. Targeting the B7 family of co-stimulatory molecules: successes and challenges
Lee et al. Thymic and peripheral differentiation of regulatory T cells
Fanelli et al. PD-L1 signaling on human memory CD4+ T cells induces a regulatory phenotype
Belizário et al. Thymic and Postthymic Regulation of Naïve CD4+ T‐Cell Lineage Fates in Humans and Mice Models
US11022615B2 (en) Regulatory T-cells, method for their isolation and uses
Miao et al. Functional defects of Treg cells: New targets in rheumatic diseases, including ankylosing spondylitis
Keller et al. Reciprocal crosstalk between dendritic cells and natural killer T cells: mechanisms and therapeutic potential
WO2010102278A1 (en) Methods and compositions for the generation and maintenance of regulatory t cells
Pesenacker et al. T regulatory cells in childhood arthritis–novel insights
d'Hennezel et al. IL-2 as a therapeutic target for the restoration of Foxp3+ regulatory T cell function in organ-specific autoimmunity: implications in pathophysiology and translation to human disease
Deng et al. FOXP3+ regulatory T cells and age‐related diseases
Raugh et al. Nature vs. nurture: FOXP3, genetics, and tissue environment shape Treg function
Li et al. Research advances on targeted-Treg therapies on immune-mediated kidney diseases
Valentini et al. Regulatory T-cell dysfunction and its implication for cell therapy
Li et al. Harnessing memory adaptive regulatory T cells to control autoimmunity in type 1 diabetes
Andersson et al. CD4+ CD25+ regulatory T cells are activated in vivo by recognition of self
He et al. Stabilizing human regulatory T cells for tolerance inducing immunotherapy